Anzeige
Mehr »
Login
Mittwoch, 28.07.2021 Börsentäglich über 12.000 News von 669 internationalen Medien
Countdown: Die derzeit größte Kurswette mit Ansage!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A16820 ISIN: DE000A168205 Ticker-Symbol: SVE 
Xetra
27.07.21
17:36 Uhr
139,00 Euro
-1,00
-0,71 %
1-Jahres-Chart
SHAREHOLDER VALUE BETEILIGUNGEN AG Chart 1 Jahr
5-Tage-Chart
SHAREHOLDER VALUE BETEILIGUNGEN AG 5-Tage-Chart
RealtimeGeldBriefZeit
138,00140,0010:00
Dow Jones News
219 Leser
Artikel bewerten:
(1)

Form 8 - Shareholder Value Beteiligungen AG: 8.3 Immunodiagnostic Holding PLC

DJ Form 8 - Shareholder Value Beteiligungen AG: 8.3 Immunodiagnostic Holding PLC

Shareholder Value Beteiligungen AG (IDH) 
Form 8 - Shareholder Value Beteiligungen AG: 8.3 Immunodiagnostic Holding PLC 
28-May-2021 / 10:33 CET/CEST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
FORM 8.3 
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY 
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 
Rule 8.3 of the Takeover Code (the "Code") 
 
1. KEY INFORMATION 
 
(a) Full name of discloser:                                  Shareholder Value 
                                                Beteiligungen AG 
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): 
                                                n.a. 
 The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), 
settlor and beneficiaries must be named. 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:    Immunodiagnostic Systems 
                                                Holding 
 Use a separate form for each offeror/offeree 
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify    n.a. 
identity of offeror/offeree: 
(e) Date position held/dealing undertaken: 
                                                17/05/2021 
 For an opening position disclosure, state the latest practicable date prior to the disclosure 
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect 
of any other party to the offer?                                NO 
 If it is a cash offer or possible cash offer, state "N/A" 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 
 
 
 
                                          Interests   Short positions 
 
                                          Number  %  Number    % 
(1) Relevant securities owned and/or controlled:                  2.809.351 9,76 
(2) Cash-settled derivatives: 
 
 
(3) Stock-settled derivatives (including options) and agreements to purchase/sell: 
 
                                          2.809.351 9,76 
 TOTAL: 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1 (c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Purchase/sale 
Class of relevant security        Number of securities Price per unit 
 
 
 
 

(b) Cash-settled derivative transactions

Product    Nature of dealing 
Class of relevant description                              Number of reference Price per 
security            e.g. opening/closing a long/short position, increasing/ securities      unit 
         e.g. CFD   reducing a long/short position 
 
 
 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Type 
Class of   Product     Writing,      Number of securities Exercise            Option money 
relevant   description e.g. purchasing,     to which option   price per e.g.     Expiry paid/ received 
security   call option   selling, varying  relates       unit    American,  date  per unit 
                etc.                        European 
                                          etc. 
 

(ii) Exercise

Class of relevant     Product description Exercising/ exercised 
security                   against           Number of securities Exercise price per unit 
             e.g. call option 
 
 
 

(d) Other dealings (including subscribing for new securities)

Nature of dealing 
Class of relevant security                Details Price per unit (if applicable) 
              e.g. subscription, conversion 
 
 
 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to 
relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the 
disclosure and any party to the offer or any person acting in concert with a party to the offer: 
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or 
understandings, state "none" 
 
 
 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure 
and any other person relating to: 
(i) the voting rights of any relevant securities under any option; or 
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is 
referenced: 
If there are no such agreements, arrangements or understandings, state "none" 
 
 
 

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO 
Date of disclosure: 25 May 2021 
Contact name:    Simon Pliquett 
Telephone number*:  +49 / 69 66983012 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk. -----------------------------------------------------------------------------------------------------------------------

ISIN:     DE000A168205 
Category Code: FEE - Immunodiagnostic Systems Holdings PLC 
TIDM:     IDH 
LEI Code:   529900V1ZBO7TDIQX144 
Sequence No.: 108107 
EQS News ID:  1201994 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1201994&application_name=news 
 

(END) Dow Jones Newswires

May 28, 2021 04:34 ET (08:34 GMT)

SHAREHOLDER VALUE BETEILIGUNGEN-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.